Skip to main content
SpringerLink
Log in

AT1-Rezeptorblockade und renale Protektion

  • Chapter
AT1-Rezeptorblockade

  • 30 Accesses

Zusammenfassung

In einer Vielzahl experimenteller und klinischer Untersuchungen konnte nachgewiesen werden, daß die Hemmung des Angiotensin Converting Enzyme (ACE) die Progression verschiedener chronischer Nierenerkrankungen verzögert. Nach Einführung der hoch selektiv wirkenden AT1-Rezeptorantagonisten stellt sich die Frage, ob von diesen Substanzen eine den ACE-Hemmem vergleichbare nephroprotektive Wirkung ausgeht. Die in den letzten Jahren aus experimentellen und klinischen Studien gewonnenen Untersuchungsergebnisse deuten daraufhin, daß ACE-Hemmer und AT1-Rezeptorantagonisten die renale Hämodynamik und Proteinurie in ähnlicher Weise beeinflussen. Anhand von Tiermodellen mit verschiedensten künstlich induzierten Nierenerkrankungen wie einseitiger Ureterobstruktion oder Antikörper-induzierter akuter Glomerulonephritis konnte darüber hinaus gezeigt werden, daß die Blockade der AT1-Rezeptoren die Entstehung und das Fortschreiten der Niereninsuffizienz verhindert. Diese Ergebnisse sind ein deutlicher Hinweis dafür, daß sich die Niereninsuffizienz bei Patienten mit verschiedensten Nierenerkrankungen durch Blockade des Angiotensin II möglicherweise aufhalten oder verhindem läßt, was einen vielversprechenden neuen Therapieansatz darstellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bovee KC, Wong PC, Timmermans PB, Thoolen MJ (1991) Effects of the nonpeptide angiotensin II receptor antagonist DuP753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4: 327–33

    Google Scholar 

  2. Brooks DP, DePalma PD, Ruffolo RR Jr (1992) Effect of Captopril and the nonpeptide angiotensin II antagonists. SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis. J Pharmacol Exp Ther 263:422–7

    CAS  PubMed  Google Scholar 

  3. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR (1995) Short- term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25: 602–9

    Article  CAS  PubMed  Google Scholar 

  4. Burnier M, Roch Ramel F, Brunner HR (1996) Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 49: 1787–90

    Article  CAS  PubMed  Google Scholar 

  5. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR (1993) Saltdependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22: 339–47

    Article  CAS  PubMed  Google Scholar 

  6. Cachofeiro V, Nasjletti A (1991) Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Effects of N omega-nitro-L-arginine. Hypertension 18: 683–8

    Article  CAS  PubMed  Google Scholar 

  7. Clark KL, Robertson MJ, Drew GM (1993) Role of angiotensin ATI and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 109: 148–56

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. De Zeeuw D (1992) The antiproteinuric effect of angiotensin converting enzyme inhibitors in human renal disease. In: Andreucci VE, Fine LG (eds) Yearbook of Nephrology. London, Springer Verlag, pp 95–113

    Google Scholar 

  9. Fauvel JP, Velon S, Berra N, Pozet N, Madonna O, Zech P, Laville M (1996) Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 28: 259–63

    Article  CAS  PubMed  Google Scholar 

  10. Fenoy FJ, Scicli G, Carretero O, Roman RJ (1991) Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to Captopril. Hypertension 17: 1038–44

    Article  CAS  PubMed  Google Scholar 

  11. Fornes P, Richer C, Vacher E, Bruneval P, Guidicelli JF (1993) Losartan’s protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 22: 305–13

    Article  CAS  PubMed  Google Scholar 

  12. Fridman K, Andersson OK, Wysocki M, Friberg P (1997) Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 11 Suppl 2: S43–4

    CAS  PubMed  Google Scholar 

  13. Gansevoort RT, de Zeeuw D, de Jong PE (1994) Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45: 861–7

    Article  CAS  PubMed  Google Scholar 

  14. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE (1994) Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 12: S37–42

    CAS  PubMed  Google Scholar 

  15. Goldberg MR, Bradstreet TE, Mc Williams EJ, Lipert S, Bjomsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G (1995) Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25: 37–46

    Article  CAS  PubMed  Google Scholar 

  16. Ichikawa I (1996) Angiotensin II receptors and renal hemodynamics and function. Blood Press Suppl 2: 19–21

    CAS  PubMed  Google Scholar 

  17. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377: 748–50

    Article  CAS  PubMed  Google Scholar 

  18. Imamura A, Mackenzie HS, Lacy ER, Hutchison FN, Fitzgibbon WR, Ploth DW (1995) Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 47: 1394–402

    Article  CAS  PubMed  Google Scholar 

  19. Imanishi M, Yoshioka K, Okumura M, Konishi Y, Tanaka S, Fujii S, Kimura G (1997) Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. KidneyInt Suppl 63: 198–200

    Google Scholar 

  20. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K (1997) Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19: 1079–99

    Article  CAS  PubMed  Google Scholar 

  21. Jover B, Herizi A, Mimran A (1996) Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction. Hypertension 27: 79–84

    Article  CAS  PubMed  Google Scholar 

  22. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F et al. (1994) Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats. Blood Press Suppl 5:54–6

    CAS  PubMed  Google Scholar 

  23. Kohzuki M, Kanazawa M, Liu PF, Kamimoto M, Yoshida K, Saito T, Yasujima M, Sato T, Abe K (1995) Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: Chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J Hypertens 13: 1785–90

    CAS  PubMed  Google Scholar 

  24. Lafayette RA, Mayer G, Park SK, Meyer TW (1992) Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766–71

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–62

    Article  CAS  PubMed  Google Scholar 

  26. Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H (1991) Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 4: 309S-314S

    CAS  PubMed  Google Scholar 

  27. Mackenzie HS, Troy JL, Rennke HG, Brenner BM (1994) TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens Suppl 12: S11–6

    CAS  PubMed  Google Scholar 

  28. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW (1993) Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 43: 346–53

    Article  CAS  PubMed  Google Scholar 

  29. Moriyama T, Kawada N, Akagi Y, Ando A, Horio M, Yamauchi A, Nagata K, Imai E, Hori M (1997) TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy. Kidney Int Suppl 63: S232–5

    CAS  PubMed  Google Scholar 

  30. Munoz Garcia R, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Casal MC, Cachofeiro V, Lahera V (1995) Acute renal excretory actions of losartan in spontaneously hypertensive rats: Role of AT2 receptors, prostaglandins, kinins and nitric oxide. J Hypertens 13:1179–84

    Google Scholar 

  31. Nagura J, Yamamoto M, Hui C, Yasuda S, Hachisu M, Konno F (1996) Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 23: 229–35

    Article  CAS  PubMed  Google Scholar 

  32. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ (1995) The angiotensin II type 2 receptor antagonizes the growth effects of the ATI receptor: Gain-of- function study using gene transfer. Proc Natl Acad Sci USA 92: 10633–7

    Article  Google Scholar 

  33. Nakamura T, Honma H, Ikeda Y, Kuroyanagi R, Takano H, Obata J, Sato T, Kimura H, Yoshida Y, Tamura K (1994) Renal protective effects of angiotensin II receptor I antagonist CV-11974 in spontaneously hypertensive stroke-prone rats (SHR-sp). Blood Press Suppl 5: 61–6

    CAS  PubMed  Google Scholar 

  34. Nakamura T, Obata J, Onizuka M, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F (1997) Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int Suppl 63: S226–8

    CAS  PubMed  Google Scholar 

  35. Navis G, Faber HJ, de Zeeuw D, de Jong PE (1996) ACE inhibitors and the kidney. A riskbenefit assessment. Drug Saf 15:200–11

    Article  CAS  PubMed  Google Scholar 

  36. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE (1997) Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 12 Suppl 2: 19–23

    PubMed  Google Scholar 

  37. Nöda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y (1997) Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int Suppl 63: SI36–9

    Google Scholar 

  38. Obata JE, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T (1997) Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 52 Suppl 63: 229–31

    Google Scholar 

  39. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM (1998) Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9: 224–30

    CAS  PubMed  Google Scholar 

  40. Pechere-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Bumier M (1998) Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertension 16: 385–93

    Article  CAS  Google Scholar 

  41. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ (1993) Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 267: 657–63

    CAS  PubMed  Google Scholar 

  42. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G (1993) Short-and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4: 40–9

    CAS  PubMed  Google Scholar 

  43. Ruff D, Gazdick LP, Bermann R, Goldberg AI, Sweet CS (1996) Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertension 14: 263–70

    Article  CAS  Google Scholar 

  44. Swartz SL, Williams GH, Hollenberg NK, Moore TJ, Dluhy RG (1979) Converting enzyme inhibition in essential hypertension: The hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1: 106–11

    Article  CAS  PubMed  Google Scholar 

  45. Tolins JP, Raij L (1990) Angiotensin converting enzyme inhibitors and progression of chronic renal failure. Kidney Int Suppl 30:118–22

    Google Scholar 

  46. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S (1998) Efficiency and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 31: 684–91

    Article  CAS  PubMed  Google Scholar 

  47. Townsend R, Haggert B, Liss C, Edelman JM (1995) Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Therapy 17: 911–23

    Article  CAS  Google Scholar 

  48. Trenkwalder P, Lehtovirta M, Dahl K (1997) Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 11 Suppl 2: S81–3

    CAS  PubMed  Google Scholar 

  49. Verseput GH, Provoost AP, Braam BB, Weening JJ, Koomans HA (1997) Angiotensin-converting-enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat. J Am Soc Nephrol 8: 249–59

    CAS  PubMed  Google Scholar 

  50. Yamamoto M, Fukui M, Shou I, Wang LN, Sekizuka K, Suzuki S, Shirato I, Tomino Y (1997) Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AURA) on renal function and glomerular injury in subtotal nephrectomized rats. J Clin Lab Anal 11: 53–62

    Article  CAS  PubMed  Google Scholar 

  51. Ziai F, Ots M, Provoost AR, Troy JL, Rennke HG, Brenner BM, Mackenzie HS (1996) The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int Suppl 57: S132–6

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik IV: Endokrinologie und Nephrologie, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Deutschland

    Prof. A. M. Sharma, T. Maier & C. Jung

  2. Medizinische Klinik IV: Endokrinologie und Neophrologie, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, D-12200, Berlin, Deutschland

    Prof. A. M. Sharma

Authors
  1. Prof. A. M. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Medizinische Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    Peter Dominiak

  2. Abteilung für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45122, Essen, Deutschland

    Gerd Heusch

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this chapter

Cite this chapter

Sharma, A.M., Maier, T., Jung, C. (1999). AT1-Rezeptorblockade und renale Protektion. In: Dominiak, P., Heusch, G. (eds) AT1-Rezeptorblockade. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93701-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93701-9_19

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-93702-6

  • Online ISBN: 978-3-642-93701-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation